[HTML][HTML] The HBsAg Prevalence among blood donors from Eastern Mediterranean and Middle Eastern countries: a systematic review and meta-Analysis
Hepatitis monthly, 2016•ncbi.nlm.nih.gov
Results We included 66 eligible studies. The pooled prevalence of HBsAg in blood donors
of both EMRO and middle eastern (E and M) countries was 2.03%(95% confidence interval
[CI]: 1.79–2.26). In addition, the prevalence rates in the EMRO countries was 1.99%(95% CI:
1.84–2.14) and 1.62% in the Middle Eastern countries (95% CI: 1.36–1.88). The prevalence
among blood donors with more than one study was 1.58% in Egypt, 0.58% in Iran, 0.67% in
Iraq, 2.84% in Pakistan, 3.02% in Saudi Arabia, 1.68% in Turkey, and 5.05% in Yemen …
of both EMRO and middle eastern (E and M) countries was 2.03%(95% confidence interval
[CI]: 1.79–2.26). In addition, the prevalence rates in the EMRO countries was 1.99%(95% CI:
1.84–2.14) and 1.62% in the Middle Eastern countries (95% CI: 1.36–1.88). The prevalence
among blood donors with more than one study was 1.58% in Egypt, 0.58% in Iran, 0.67% in
Iraq, 2.84% in Pakistan, 3.02% in Saudi Arabia, 1.68% in Turkey, and 5.05% in Yemen …
Results
We included 66 eligible studies. The pooled prevalence of HBsAg in blood donors of both EMRO and middle eastern (E and M) countries was 2.03%(95% confidence interval [CI]: 1.79–2.26). In addition, the prevalence rates in the EMRO countries was 1.99%(95% CI: 1.84–2.14) and 1.62% in the Middle Eastern countries (95% CI: 1.36–1.88). The prevalence among blood donors with more than one study was 1.58% in Egypt, 0.58% in Iran, 0.67% in Iraq, 2.84% in Pakistan, 3.02% in Saudi Arabia, 1.68% in Turkey, and 5.05% in Yemen.
Conclusions
Based on the WHO classification of hepatitis B virus (HBV) prevalence, the prevalence of HBsAg in blood donors from E and M countries reached an intermediate level. However, there were low prevalence levels in some E and M countries.
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果